Actualités Neurobiological Technologies (MM) - NTII | Actions NASDAQ

Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program

EMERYVILLE, Calif., June 1 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NASDAQ:NTII) (NTI(R)) today announced that Celtic...

- Quarterly Report (10-Q)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark...

Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results

EMERYVILLE, Calif., May 8 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (NASDAQ:NTII) today announced financial results...

Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine

EMERYVILLE, Calif., May 1 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (NASDAQ:NTII), today announced it has received a...

Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company

EMERYVILLE, Calif., March 26 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (NASDAQ:NTII) announced today that it has...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13...

- Amended Statement of Ownership (SC 13G/A)

- Amended Statement of Ownership (SC 13G/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of...

- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

- Quarterly Report (10-Q)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark...

Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results

EMERYVILLE, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (NASDAQ:NTII) today announced financial...

- Amended Current report filing (8-K/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or...

Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO

EMERYVILLE, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (NASDAQ:NTII), today announced the appointment...

Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine

EMERYVILLE, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (NASDAQ:NTII), today announced it has received...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Neurobiological Technologies (MM) (NTII)

Outils de qualité professionnelle, pour des investisseurs individuels.

NTII Actualités

Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program

- Quarterly Report (10-Q)

Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results

Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine

Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company

- Current report filing (8-K)

- Amended Statement of Ownership (SC 13G/A)

- Amended Statement of Ownership (SC 13G/A)

- Statement of Changes in Beneficial Ownership (4)

- Quarterly Report (10-Q)

Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results

- Amended Current report filing (8-K/A)

- Current report filing (8-K)

Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO

Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Neurobiological Technologies (MM) (NTII) Actualités

Neurobiological Technologies (MM) (NTII)

Outils de qualité professionnelle, pour des investisseurs individuels.

NTII Actualités

Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program

- Quarterly Report (10-Q)

Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results

Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine

Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company

- Current report filing (8-K)

- Amended Statement of Ownership (SC 13G/A)

- Amended Statement of Ownership (SC 13G/A)

- Statement of Changes in Beneficial Ownership (4)

- Quarterly Report (10-Q)

Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results

- Amended Current report filing (8-K/A)

- Current report filing (8-K)

Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO

Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités